Investigating how a protein complex helps glioblastoma patients recover from chemotherapy-induced DNA damage
Role of RBBP4/p300 Complex in Recovery from therapy induced DNA damage in glioblastoma
This study is looking at how a specific protein complex can help glioblastoma patients recover from DNA damage caused by the chemotherapy drug temozolomide, with the hope of finding better ways to make treatments work more effectively for you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10870208 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the RBBP4/p300 protein complex in helping glioblastoma patients recover from DNA damage caused by the chemotherapy drug temozolomide (TMZ). The study examines how this complex influences the repair of DNA damage and the effectiveness of treatment. By using animal models and patient-derived samples, researchers will explore how manipulating this protein complex can enhance the sensitivity of glioblastoma cells to chemotherapy and improve treatment outcomes. The goal is to identify new therapeutic strategies that could make existing treatments more effective for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with newly diagnosed glioblastoma who are undergoing treatment with temozolomide.
Not a fit: Patients with glioblastoma who are not receiving chemotherapy or those with advanced disease stages may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies that enhance the effectiveness of chemotherapy for glioblastoma patients.
How similar studies have performed: Other research has shown promising results in enhancing chemotherapy effectiveness through similar mechanisms, indicating potential for success in this approach.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Kitange, Gaspar Julius — University of Minnesota
- Study coordinator: Kitange, Gaspar Julius
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.